



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/954,904	,904 09/18/2001		Jie Zhang	8747.82	8603
20551	7590	08/11/2005		EXAM	INER
		WESTERN, LLP	GEORGE, KONATA M		
8180 SOUTH 700 EAST, SUITE 200 P.O. BOX 1219 SANDY, UT 84070				ART UNIT	PAPER NUMBER
				1616	

DATE MAILED: 08/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	T A 12 42 A1	I A I				
	Application No.	Applicant(s)				
Office Antique Comments	09/954,904	ZHANG ET AL.				
Office Action Summary	Examiner	Art Unit				
	Konata M. George	1616				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with th	e correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply b ly within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS f e, cause the application to become ABANDC	e timely filed  days will be considered timely.  rom the mailing date of this communication.  NED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 03 J	<u>une 2003</u> .	•				
2a) This action is <b>FINAL</b> . 2b) ☐ This	s action is non-final.	•				
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ☐ Claim(s) 1-6,11-14,17 and 19-28 is/are pendir 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) 29-32 is/are allowed. 6) ☐ Claim(s) 1-6, 11-14, 17 and 19-28 is/are reject 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers	ted.					
9) The specification is objected to by the Examine		oo Evaminor				
10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct	• • • • • • • • • • • • • • • • • • • •	· ·				
11) The oath or declaration is objected to by the Ex						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applic prity documents have been rece tu (PCT Rule 17.2(a)).	cation No eived in this National Stage				
•						
Attachment(s)	_					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summ Paper No(s)/Ma ) 5) Notice of Inform 6) Other:					

Office Action Summary

Application/Control Number: 09/954,904

Art Unit: 1616

#### **DETAILED ACTION**

Claims 1-6, 11-14, 17 and 19-32 are pending in this application.

## Request for Continued Examination (RCE)

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 3, 2005 has been entered.

### **Action Summary**

- 2. Examiner acknowledges the addition of claims 24-32.
- 3. The rejection of claims 1-6, 11-14, 17 and 19-23 under 35 U.S.C. 103(a) over Argaud is hereby withdrawn as applicant has amended the claims to state that the temperature modification apparatus is a separate unit for the dermal drug delivery system.

### Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA

Application/Control Number: 09/954,904

Art Unit: 1616

1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-6, 11-14, 17 and 19-28 are rejected under the judicially created doctrine 4. of obviousness-type double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 6.245,347 B1, claims 1-7 of U.S. Patent No. 6,488,959 B2 and claims 1-17 of U.S. Patent No. 6,756,053 B2. Although the conflicting claims are not identical, they are not patentably distinct from each other because all of the instant invention and the above mentioned patents are all directed towards a drug delivery device system and a method of delivering the drug via a patch system comprising a patch containing the drug and a heat delivering device placed on top of the drug. The difference between the instant application and the patents is the limitation of heating the skin to pre-determined temperature range and a pre-determined duration of time. To one of ordinary skill a pre-determined temperature and pre-determined duration of time would have been obvious when formulating a dosage form for delivery of a drug to the skin. One would want the optimum temperature to facilitate the drug passing through the skin and not to hot to burn the skin of degrade the drug. The pre-determined time would also have been obvious to ensure that the right amount of drug is being administered to the body.

Application/Control Number: 09/954,904

Art Unit: 1616

Conclusion

5. Claims 1-6, 11-14, 17 and 19-28 are rejected.

6. Claims 29-32 are allowed. The prior art does not teach the invention as claimed

in claim 29.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Konata M. George, whose telephone number is

(571) 272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday

to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for

the organization where this application or proceeding is assigned are (703) 872-9306 for

regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is

(571) 272-1600.

Konata M. George

SUPERVISORY PATENT FYAMI

UPERVISONY MATERITE ZAMINER

Page 4